Epizyme reported $11.12M in Equity Capital and Reserves for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Agios Pharmaceuticals AGIO:US $ 1124.07M 83.38M
Amarin AMRN:US $ 580.04M 61.07M
Amgen AMGN:US $ 2419M 1503M
Avrobio Inc AVRO:US $ 143.16M 26.31M
Biogen BIIB:US $ 11872.5M 630.2M
Bluebird Bio BLUE:US $ 180.12M 83.14M
Cerulean Pharma CERU:US $ 30.88M 7.88M
Daiichi Sankyo 4568:JP Y 1400252M 49380M
Eisai 4523:JP Y 804545M 55723M
Epizyme EPZM:US $ 11.12M 31.81M
Exelixis EXEL:US $ 2293.85M 83.24M
Gilead Sciences GILD:US $ 20215M 288M
Glaxosmithkline GSK:US $ 16374M 193M
GlaxoSmithKline GSK:LN 16374M 193M
Karyopharm Therapeutics KPTI:US $ -116338000 33.26M
Macrogenics MGNX:US $ 178.21M 61.4M
Novartis NVS:US $ 62925M 1385M
Novartis NOVN:VX SF 62925M 1385M
Regeneron Pharmaceuticals REGN:US $ 20687.8M 773.1M
Seattle Genetics SGEN:US $ 2932.81M 65.66M
Spectrum Pharmaceuticals SPPI:US $ 55.26M 7.7M
Vertex Pharmaceuticals VRTX:US $ 11933.5M 1026.5M
Xencor XNCR:US $ 742.34M 20.68M